# reload+after+2024-01-22 23:43:17.319881
address1§210 East Grand Avenue
city§South San Francisco
state§CA
zip§94080
country§United States
phone§650 457 2700
website§https://www.allogene.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO- 316, an allogeneic CAR T cell product candidates for the treatment of immune checkpoint inhibitor; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
fullTimeEmployees§359
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Arie S. Belldegrun F.A.C.S., M.D.', 'age': 74, 'title': 'Co-Founder & Executive Chairman', 'yearBorn': 1949, 'fiscalYear': 2022, 'totalPay': 714248, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. David D. Chang M.D., Ph.D.', 'age': 63, 'title': 'Co-Founder, President, CEO & Director', 'yearBorn': 1960, 'fiscalYear': 2022, 'totalPay': 1100480, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Joshua A. Kazam', 'age': 46, 'title': 'Co-Founder & Director', 'yearBorn': 1977, 'fiscalYear': 2022, 'totalPay': 711000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Geoffrey M. Parker', 'age': 59, 'title': 'Executive VP & CFO', 'yearBorn': 1964, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Timothy L. Moore Ph.D.', 'age': 62, 'title': 'Executive VP & Chief Technical Officer', 'yearBorn': 1961, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Earl M. Douglas Esq.', 'age': 60, 'title': 'General Counsel & Compliance Officer', 'yearBorn': 1963, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Susan R. Lundeen', 'age': 57, 'title': 'Chief People Officer', 'yearBorn': 1966, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Christine  Cassiano', 'title': 'Executive VP, Chief Corporate Affairs & Brand Strategy Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Zachary J. Roberts M.D., Ph.D.', 'age': 45, 'title': 'Executive VP of Research & Development and Chief Medical Officer', 'yearBorn': 1978, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Yinlin  Chen', 'title': 'Senior Vice President of Finance', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§2
boardRisk§9
compensationRisk§10
shareHolderRightsRisk§8
overallRisk§9
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§0.759
priceToSalesTrailing12Months§2637.2441
currency§USD
dateShortInterest§1702598400
forwardEps§-1.82
pegRatio§-1.66
exchange§NMS
quoteType§EQUITY
shortName§Allogene Therapeutics, Inc.
longName§Allogene Therapeutics, Inc.
firstTradeDateEpochUtc§1539264600
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§074a6d28-e148-3d16-a323-524e6da42340
gmtOffSetMilliseconds§-18000000
targetHighPrice§35.0
targetLowPrice§4.5
targetMeanPrice§13.43
targetMedianPrice§13.0
recommendationMean§1.8
recommendationKey§buy
numberOfAnalystOpinions§14
quickRatio§12.411
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
